

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David Foster
Date of last notice	26 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Terry Foster + Ms Vickey S Foster - beneficiary Citicorp Nominees Pty Limited – beneficiary Citicorp Nominees Pty Limited – beneficiary
Date of change	10 December 2024
No. of securities held prior to change	
David Foster	5,646,829 fully paid ordinary shares 500,000 listed options exercisable at \$0.06 expiring 14 March 2025
Mr Terry Foster + Ms Vickey S Foster <Foster Living Account>	105,740 fully paid ordinary shares 20,588 listed options exercisable at \$0.06 expiring 14 March 2025
Citicorp Nominees Pty Limited	71,303 fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Options exercisable at \$0.15 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months)
Number acquired	4,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$4,000
No. of securities held after change David Foster Mr Terry Foster + Ms Vickey S Foster <Foster Living Account> Citicorp Nominees Pty Limited	5,646,829 fully paid ordinary shares 500,000 listed options exercisable at \$0.06 expiring 14 March 2025 4,000,000 options exercisable at \$0.15 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months) 105,740 fully paid ordinary shares 20,588 listed options exercisable at \$0.06 expiring 14 March 2025 71,303 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options approved at AGM held on 19 November 2024

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ISLAND PHARMACEUTICALS LIMITED
ABN	48 641 183 842

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Ntoumenopoulos
Date of last notice	5 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Sobol Capital Pty Ltd ATF Sobol Capital Trust (Sole Director) Christopher Ntoumenopoulos & Leo Ntoumenopoulos ATF The Ntoumenopoulos Superannuation Fund (Trustee & Beneficiary)
Date of change	10 December 2024

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p> <p>(1) Sobol Capital Pty Ltd ATF Sobol Capital Trust (Sole Director)</p> <p>(2) Christopher Ntoumenopoulos & Leo Ntoumenopoulos ATF The Ntoumenopoulos Superannuation Fund (Trustee & Beneficiary)</p>	<ul style="list-style-type: none"> • 714,286 fully paid ordinary shares • 357,143 options exercisable at \$0.07 expiring 4 December 2025 • 357,143 options exercisable at \$0.07 expiring 4 December 2026 • 974,850 fully paid ordinary shares • 487,425 options exercisable at \$0.07 expiring 4 December 2025 • 487,425 options exercisable at \$0.07 expiring 4 December 2026
<p>Class</p>	<p>Options exercisable at \$0.10 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months)</p>
<p>Number acquired</p> <p>Christopher Ntoumenopoulos</p>	<p>2,000,000</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$2,000</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change</p> <p>(1) Sobol Capital Pty Ltd ATF Sobol Capital Trust (Sole Director)</p> <p>(2) Christopher Ntoumenopoulos & Leo Ntoumenopoulos ATF The Ntoumenopoulos Superannuation Fund (Trustee & Beneficiary)</p> <p>(3) Christopher Ntoumenopoulos</p>	<ul style="list-style-type: none"> • 714,286 fully paid ordinary shares • 357,143 options exercisable at \$0.07 expiring 4 December 2025 • 357,143 options exercisable at \$0.07 expiring 4 December 2026 • 974,850 fully paid ordinary shares • 487,425 options exercisable at \$0.07 expiring 4 December 2025 • 487,425 options exercisable at \$0.07 expiring 4 December 2026 • 2,000,000 options exercisable at \$0.10 expiring 10 December 2027, vesting 50% on 10 December 2025 (12 months) and 50% on 10 December 2026 (24 months)
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of options approved at AGM held on 19 November 2024</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change</p> <p>Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.